GlobeNewsWire
21 Jul 2026, 11:50 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Helus Pharma completed enrollment for the Phase 3 APPROACH study of HLP003 ahead of schedule. — Faster-than-expected enrollment reduces clinical trial risk and accelerates the path to a potential market-moving data readout.
+0.40Topline data for the APPROACH study is expected to be released in Q4 2026. — This provides a clear catalyst date for investors, though the actual market move will depend on the results.
+0.30The company targets a potential FDA New Drug Application (NDA) for HLP003 in 2028. — Establishes the long-term commercialization timeline, though it is several years away.
+0.20HLP003 has previously received Breakthrough Therapy Designation from the FDA. — FDA designation indicates regulatory support and potentially an expedited review process, increasing the probability of success.
Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company completed its Phase 3 study enrollment ahead of schedule and reported strong previous Phase 2 efficacy data.
The company reported significant year-over-year and quarter-over-quarter sales growth for its drug SPRAVATO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
